| Title |
Fluorescent Affibody Peptide Penetration in Glioma Margin Is Superior to Full Antibody
|
|---|---|
| Published in |
PLOS ONE, April 2013
|
| DOI | 10.1371/journal.pone.0060390 |
| Pubmed ID | |
| Authors |
Kristian Sexton, Kenneth Tichauer, Kimberley S. Samkoe, Jason Gunn, P. Jack Hoopes, Brian W. Pogue |
| Abstract |
Fluorescence imaging has the potential to significantly improve neurosurgical resection of oncologic lesions through improved differentiation between normal and cancerous tissue at the tumor margins. In order to successfully mark glioma tissue a fluorescent tracer must have the ability to penetrate through the blood brain barrier (BBB) and provide delineation in the tumor periphery where heterogeneously intact BBB may exist. In this study it was hypothesized that, due to its smaller size, fluorescently labeled anti-EGFR Affibody protein (∼7 kDa) would provide a more clear delineation of the tumor margin than would fluorescently labeled cetuximab, a full antibody (∼150 kDa) to the epidermal growth factor receptor (EGFR). |
Mendeley readers
The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Unknown | 59 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 15 | 25% |
| Student > Master | 10 | 17% |
| Student > Bachelor | 6 | 10% |
| Researcher | 5 | 8% |
| Professor > Associate Professor | 4 | 7% |
| Other | 9 | 15% |
| Unknown | 11 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 15% |
| Agricultural and Biological Sciences | 9 | 15% |
| Chemistry | 8 | 13% |
| Biochemistry, Genetics and Molecular Biology | 7 | 12% |
| Engineering | 6 | 10% |
| Other | 8 | 13% |
| Unknown | 13 | 22% |